Methods of inhibiting p38 with substituted bicyclic pyrimidines

Details Methods of inhibiting p38 with substituted bicyclic pyrimidines Methods of inhibiting p38 with substituted bicyclic pyrimidines

2005-08-12

2008-11-11

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000, C544S278000, C514S300000, C514S301000, C514S302000, C546S114000, C546S115000, C546S116000, C546S113000

Reexamination Certificate

active

07449472

ABSTRACT:
The present invention discloses compounds corresponding to the formulawherein A, X, Y, R, R1and R2are as defined within, pharmaceutical formulations, methods of making and uses thereof.

REFERENCES:
patent: 4835157 (1989-05-01), Press et al.
patent: 2001/0020030 (2001-09-01), Stewart et al.
patent: 2005/0004142 (2005-01-01), Adams et al.
patent: WO 95/29897 (1995-11-01), None
patent: WO 95/33748 (1995-12-01), None
patent: WO 95/33752 (1995-12-01), None
patent: WO 98/01428 (1998-01-01), None
patent: WO 98/08382 (1998-03-01), None
patent: WO 00/39108 (2000-07-01), None
patent: WO 00/43394 (2000-07-01), None
patent: WO 01/49688 (2001-07-01), None
patent: WO 02/14317 (2002-02-01), None
J. W. Fijen*, J. G. Zijlstra*, P. De Boer, R. Spanjersberg*, J. W. Cohen Tervaert, T. S. Van Der Werf*, J. J. M. Ligtenberg* & J. E. Tulleken*, Clinical & Experimental Immunology vol. 124, Issue 1, p. 16—Apr. 2001.
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S., Gastroenterology. Jan. 2002;122(1):7-14 . . . PMID: abstract 11781274.
Hashimoto S, Gon Y, Matsumoto K, Maruoka S, Takeshita I, Hayashi S, Asai Y, Jibiki I, Machino T, Horie T., J Pharmacol Exp Ther. May 2000;293(2):370-5.
Esper A.M; Expert Opin. Investig. Drugs, 2005, 14(5), 633-645).
Palmer, Trends in Pharmacological Sciences, 2002, 23(9), 426-433.
Jones et al, “British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.” Gut 2000, (Suppl II)47:ii1-ii19.
Hurst, Derek T. An Introduction to the Chemistry and Biochemistry of the Pyrimidines, Purines, and Pteridines, London: John Wiley and Sons. 1980 pp. 26-27.
Ganghyeok Kim et al, “Design, Synthesis, and Evaluation of 1,5-Disu”,Array Biopharma, [online] no date [retrieved on Apr. 28, 2005]. Retrieved from the Internet, <http://media.corporate-ir.net/media—files
sd/arry/posters/0304ACS-Anaheim-Poster.pdf>.
Michael Greer, “HIV/AIDS Dementia: CPI-1189 safe but ineffective”, AIDSWEEKLY Plus; [online] AIDSWEEKLY Plus; Monday, Jan. 20, 2003 [retrieved on Apr. 28, 2005]. Retrieved from the Internet, <http://www.aegis.com/pubs/aidswkly/2003/AW030107.html>.
Trejo, Alejandra, et al, “Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase”,J. Med. Chem., 2003, 46:4702-4713.
Wolff, Manfred E., Burger's Medicinal Chemistry, 5ed, Part I:, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S., et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451-596.
Henry, James R., et al., “6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H- pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor”,J. Med. Chem, 1998, 41: 4196-4198.
Koch, A., et al., “Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages”,Eur. Respir. J., 2004, 23:805-812.
Noble, Martin E. M., et al., “Protein Kinase Inhibitors: Insights into Drug Design from Structure”, Science, 2004, 303: 1800-1804.
Branger, J. et al, “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia”.J Immunol(2002) 168:4070-77.
English, J.M. et al, “Pharmacological inhibitors of MAPK pathways”,Trends in Pharmacol Sci(2002) 23(1):40-45.
Müller, T.,Curr Opin Invest Drugs(2002) 3(12):1763-67.
Noble, Martin E.M., et al, “Protein Kinase Inhibitors: Insights into Drug Design from Structure”,Science(2004) 303:1800-05.
Parasrampuria, D.A. et a;, “Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitor: A First-in-Human Study”,J Clin Pharmacol(2003) 43:406-13.

Affiliated with

Also associated with

Rating

Methods of inhibiting p38 with substituted bicyclic pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting p38 with substituted bicyclic pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting p38 with substituted bicyclic pyrimidines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4037724